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Abstract
Prevention of genital herpes is a global health priority. B5, a recently identified ubiquitous human protein, was proposed as
a candidate HSV entry receptor. The current studies explored its role in HSV infection. Viral plaque formation was reduced
by ,90% in human cells transfected with small interfering RNA targeting B5 or nectin-1, an established entry receptor.
However, the mechanisms were distinct. Silencing of nectin-1 prevented intracellular delivery of viral capsids, nuclear
transport of a viral tegument protein, and release of calcium stores required for entry. In contrast, B5 silencing had no effect
on these markers of entry, but inhibited viral protein translation. Specifically, viral immediate early genes, ICP0 and ICP4,
were transcribed, polyadenylated and transported from the nucleus to the cytoplasm, but the viral transcripts did not
associate with ribosomes or polysomes in B5-silenced cells. In contrast, immediate early gene viral transcripts were detected
in polysome fractions isolated from control cells. These findings are consistent with sequencing studies demonstrating that
B5 is eukaryotic initiation factor 3 subunit m (eIF3m). Although B5 silencing altered the polysome profile of cells, silencing
had little effect on cellular RNA or protein expression and was not cytotoxic, suggesting that this subunit is not essential for
host cellular protein synthesis. Together these results demonstrate that B5 plays a major role in the initiation of HSV protein
translation and could provide a novel target for strategies to prevent primary and recurrent herpetic disease.
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Introduction
Herpes simplex viruses (HSV) are the leading cause of genital
herpes worldwide, the most common infection associated with
neonatal encephalitis, and a major co-factor for HIV infection,
thus underscoring the urgency to develop novel prevention
strategies [1]. Notably, the epidemiology of genital herpes may
be changing as recent studies indicate that HSV-1 accounts for a
significant proportion of new infections, particularly in the
developed world [2,3]. Identifying new approaches to prevent
infection by both serotypes requires an understanding of the
pathways required for the establishment of primary and recurrent
infection and the cellular factors usurped by the viruses to promote
infection.
Preventing HSV entry has proved difficult, reflecting the
complexity of this process, which involves interactions between
several viral envelope glycoproteins and cellular receptors and
activation of calcium signaling pathways. Both serotypes (HSV-1
and HSV-2) initiate infection by binding to heparan sulfate
moieties on syndecan proteoglycans [4,5,6,7]. Glycoprotein D (gD)
then engages one of several entry receptors, most commonly
nectin-1 or herpes virus entry mediator (HVEM) [8,9]. Studies
with human epithelial cells indicate that these viral-cell interac-
tions trigger the release of calcium (Ca
2+) near the plasma
membrane, which is followed by activation of the inositol
triphosphate receptor, resulting in the rapid release of endoplasmic
reticulum (ER) Ca
2+ stores [4,10]. This release of ER stores
requires the concerted activities of glycoproteins B, D, and hetero-
oligomers of H and L and blockade of the Ca
2+ response prevents
viral entry.
Recent work suggested that another cellular protein also may
play a role in HSV entry. Porcine renal epithelial cells, which are
naturally resistant to HSV entry, were rendered fully susceptible
following transfection with a cDNA encoding human hfl-B5
[11,12,13,14]. The B5 protein was found to be ubiquitously
expressed on multiple human cell lines and a synthetic 30-mer
peptide containing the sequence found in the C-terminus of B5
inhibited HSV infection at a step following viral attachment [14].
Recent genetic studies demonstrate that B5 is identical to the
sequence that encodes for subunit m of eukaryotic initiation factor
3 (eIF3m) [15]. Building from these observations, we sought to
further explore the role B5 (eiF3m) plays in HSV infection of
human cells and whether it could provide a target for the
development of novel prevention strategies.
Results
Silencing of B5 inhibits HSV infection
CaSki (human cervical epithelial) cells were transfected with
siRNA targeting B5, nectin-1, an established entry co-receptor, or
as a control, HVEM, an alternative co-receptor that is not
expressed at detectable levels on CaSki cells [4]. Silencing resulted
in reductions of 80–95% in protein and RNA expression by
Western blot and quantitative real time PCR (qRT-PCR),
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and B) or with a non-specific control siRNA (not shown). Silencing
was specific, as transfection with siB5 had no impact on nectin
expression and, conversely, transfection with siNectin had no effect
on B5 expression. To determine whether silencing impacted HSV
infection, CaSki cells were transfected with siB5, siNectin, or
siHVEM. The transfected cells were infected with HSV-2(G) or
HSV-1(KOS) 48 h post-transfection and viral plaques were
quantified. Transfection with siB5 or siNectin reduced HSV-2
plaque formation by 98.660.8 and 86.563.5% respectively and
HSV-1 plaque formation by 68615 and 66611%, respectively,
relative to cells transfected with a non-specific control siRNA,
whereas silencing of HVEM had little or no effect (Fig. 1C).
Transfection with each individual siRNA targeting B5 also
resulted in a reduction in B5 protein expression and concomitant
inhibition of HSV-2 plaque formation, although siB5#1 was the
least efficient (Fig. 1D). Importantly, transfection with siB5 was not
cytotoxic and did not trigger any significant interferon response
(not shown). Together, these findings support a role for B5 in HSV
infection.
B5 is not required for HSV entry
Several parallel strategies were adopted to determine whether
B5 silencing interfered with viral entry. VP16 is a virion tegument
protein delivered to the nucleus following HSV entry and thus
serves as a surrogate marker of viral entry. CaSki cells were
transfected with nectin-1, control, or B5 specific siRNA, and then
48 h later, synchronously infected with HSV-2(G) (moi 1 pfu/cell).
Forty-five minutes post-shift of the temperature to 37uC, cells were
harvested and nuclear extracts were prepared and evaluated for
Figure 1. Silencing of B5 and nectin-1 reduces HSV infection. (A). CaSki cells were transfected with siHVEM (control), B5 or nectin-1-specific
pools of siRNA and 48 h post-transfection, immunoblots of cell lysates were prepared and probed with anti-B5 polyclonal Ab or anti-nectin mAb and
then stripped and probed for b-actin expression. (B) Western blots were scanned for protein expression (odu). In parallel studies, RNA was extracted
from transfected cells and analyzed by qRT-PCR for expression of B5 and nectin. Results are presented as protein or RNA expression as a percentage
of cells transfected with siHVEM and are means 6 sd obtained from 3 different experiments. (C) The transfected cells were infected with HSV-2(G) or
HSV-1(KOS) (48 h post-transfection) and the ability to support viral plaque formation determined by counting plaques after 48 h incubation by
immunostaining. Results are presented as pfu/well as a percentage of pfu/well formed in cells transfected with non-specific control siRNA and are
means + sd from 2 independent experiments conducted in quadruplicate. (D) Cells were transfected independently with each siB5, with the pool of
three siRNAs or with siHVEM (control) and 48 h post-transfection immunoblots of cell lysates were prepared and probed with anti-B5 polyclonal Ab
and b-actin and relative expression determined after scanning the blots. Results are presented as odu relative to cells transfected with siHVEM. In
parallel, the transfected cells were infected with HSV-2(G) and the ability to support viral plaque formation determined by counting plaques after
48 h incubation by immunostaining. Results are presented as pfu/well as percentage of pfu/well formed in cells transfected with siHVEM and are
means 6 sd from a representative experiment conducted in duplicate.
doi:10.1371/journal.pone.0011829.g001
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nuclear protein histone-1 was included as a control. As
anticipated, silencing of nectin-1 significantly blocked the nuclear
transport of VP16 by 78615% (p,0.01, t-test), consistent with a
block to viral entry, whereas silencing of B5 had no impact on
VP16 nuclear delivery relative to cells transfected with control
siRNA (Fig. 2A).
We also applied confocal microscopy to directly monitor the
intracellular delivery of viral capsids. CaSki cells were transfected
with each of the siRNAs and 48 h later, synchronously infected
(moi 5 pfu/cell) with purified KVP26GFP, an HSV-1 variant
expressing a VP26–GFP fusion capsid protein, for which the viral
envelope was also labeled with a fluorescent long-chain carbocya-
nine dye, DiI [4,16]. This enabled discrimination between bound
viral envelopes (red) and intracellularly delivered capsids (green).
Notably, as previously reported, the GFP fluorescence in the
capsid is only visualized after viral de-envelopment when the viral
envelope is labeled with DiI [4]. The cells were stained with EZ-
Link Sulfo-NHS-Biotin to detect plasma membranes (blue) before
infection and were fixed 15 minutes after entry. Bound viral
envelopes (red) were readily detected in all of the transfectants.
However, while viral capsids (green) were observed in the majority
of cells transfected with siHVEM (control) or B5-specific siRNA,
they were seen in fewer than 6% of cells transfected with nectin-1
siRNA (Fig. 2B).
The block to entry in response to nectin-1, but not B5 silencing,
was further confirmed by comparing the intracellular Ca
2+
response to HSV-2(G) (moi 5) by live confocal microscopy [4].
We previously reported that HSV triggers the release of
intracellular Ca
2+, which promotes viral entry. Viral envelopes
(DiO labeled, green) were readily detected bound to the plasma
membrane (blue) of cells 10 minutes after the temperature reached
37uC, but release of intracellular Ca
2+ (crimson) was only observed
in the control or siB5 transfected cells, not the siNectin-1
Figure 2. Silencing of nectin, but not B5, prevents HSV entry. (A). CaSki cells were transfected with siNectin, siHVEM or siB5 and then 48 h
later, synchronously infected with HSV-2(G) and 45 min after the temperature shift to 37uC, nuclear extracts were prepared and analyzed for presence
of viral VP16 by Western blot; expression of histone-1 was included as a control. The bar graph depicts expression of VP16 relative to histone-1;
results are representative of three independent experiments. (B). Cells were transfected with siRNA and then 48 h post-transfection, infected with DiI-
envelope labeled KVP26GFP and 15 min later, fixed and stained for plasma membrane (blue) and analyzed by confocal microscopy. Images are
representative of 3 independent experiments: 100 cells were counted and the bar graph depicts percentage of cells expressing bound virus (red
envelope) and viral capsids (green). (C). Representative 3-dimensional images obtained by live confocal microscopy of transfected cells, stained for
plasma membrane (blue), loaded with Calcium Crimson and then synchronously infected with DiO-envelope labeled HSV-2(G) (green). Images shown
were obtained 10 min after being placed in a 37uC temperature-controlled chamber. The bar graph on the right depicts relative intensity obtained
from scanning 10 cells per field of vision from two independent experiments.
doi:10.1371/journal.pone.0011829.g002
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2+ response was
detected in cells transfected with siNectin as late as 30 minutes
following infection (not shown). Additionally, phosphorylation of
focal adhesion kinase, a cellular response to viral entry that
promotes transport of the viral capsids to the nuclear pore, was
observed following HSV infection of cells transfected with siB5,
but not cells transfected with siNectin (not shown) [17]. Together,
these findings demonstrate that B5 contributes to HSV infection at
a step downstream of viral entry and nuclear transport.
B5 plays key role in the translation of HSV proteins
The finding that the sequence for B5 is identical to that of
eIF3M [15] suggested that B5 might participate in the initiation of
viral protein translation. To address this possibility, CaSki cells
were again transfected with siB5 or siHVEM as a control, infected
(moi 1 pfu/cell) with HSV-2(G) 48 h post-transfection, and then
nuclear or whole cell lysates prepared at different times post-
infection (pi) were evaluated for viral protein expression by
Western blots. Incoming VP16 was readily detected in nuclear
extracts prepared 45 min post-HSV-2 infection in cells transfected
with siHVEM (control) and siB5, reflecting the absence of any
block to viral entry or nuclear transport. However, 4 h pi, little or
no newly synthesized VP16 could be detected in cells transfected
with siB5 compared to cells transfected with siHVEM (Fig. 3A).
Comparable results were obtained for other viral proteins
including thymidine kinase and gB (not shown). A marked
reduction in expression of viral immediate early genes (ICP0,
ICP4 and ICP27) was observed in whole cell lysates harvested 4 h
pi from cells infected with HSV-1(KOS) (Fig. 3B).
To determine whether the reduction in protein expression
reflects a block in transcription or translation, transfected cells
were infected (moi 1 pfu/cell) with HSV-2(G) and then RNA was
isolated at different times pi and analyzed for the expression of
ICP0, ICP4 or gB by qRT-PCR. As an additional control, cells
were infected with virus and then treated with 100mgo f
cycloheximide, an inhibitor of protein synthesis. Neither transfec-
tion with siB5 nor treatment with cycloheximide prevented
transcription of ICP0 or ICP4 (Fig. 4). However there was a
marked reduction in gB transcripts, which presumably reflects the
requirement for ICP0 and ICP4 proteins, which are transcrip-
tional transactivators of late viral gene expression [18,19]. These
results suggest that siB5 does not block immediate early gene
expression at transcription, but blocks the translation of these viral
proteins.
Figure 3. Silencing of B5 blocks viral protein expression. (A). CaSki cells were transfected with siB5 or siHVEM and then 48 h later,
synchronously infected with HSV-2(G) and nuclear extracts harvested at the indicated times and evaluated for VP16. Blots are representative of results
obtained in 3 independent experiments. (B). Transfected cells were infected with HSV-1(KOS) and 4 h pi, cellular lysates harvested and analyzed for
the expression of ICP4, ICP0 and ICP27. Blots were scanned and the relative expression of viral proteins by odu is presented as a percentage of
expression in cells transfected with siHVEM obtained in 3 independent experiments (right).
doi:10.1371/journal.pone.0011829.g003
Figure 4. Silencing of B5 blocks translation, but not transcrip-
tion, of viral proteins. Cells were transfected with siHVEM or siB5 and
then infected with HSV-2(G) and 4 h pi, RNA was extracted and
analyzed by qRT-PCR for viral gene expression. RNA was also extracted
from non-transfected CaSki cells that had been infected with HSV-2(G)
in the presence of cycloheximide. Results are presented as RNA
expressed in siB5 transfected cells or in cells infected in the presence of
cycloheximide as a percentage of expression in siHVEM transfected cells
and are mean 6 sd obtained from 3 independent experiments.
doi:10.1371/journal.pone.0011829.g004
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interacts with viral mRNA
To explore whether B5 interacts directly with viral mRNA, cells
were infected with HSV-2(G) (2 pfu/cell) and 3, 5 or 7 h pi, the
cells were treated with formaldehyde to cross-link RNA-protein
complexes, and then the complexes were immunoprecipitated with
a polyclonal antibody to B5. Western blots confirmed that B5 was
found exclusively in the pellet (not shown). RNA was extracted
from both the supernatant and pellet and evaluated for the
presence of viral transcripts and RPLPO by qRT-PCR. The ICP4
and ICP0 transcripts were detected almost exclusively in the B5-
immunoprecipitated pellet with peak expression detected at 3 and
5 hours pi, respectively. In contrast, gB transcripts were primarily
detected in the supernatant with peak expression 7 h pi and
RPLPO transcripts, a ribosomal host cellular gene, were detected
in both the supernatant and pellet (Fig. 5A).
In parallel studies, the complexes were subjected to Western
blotting with antibodies to ICP4 or gB for HSV-2 and ICP0 for
HSV-1; ICP0 was not evaluated for HSV-2 as the antibody is
serotype specific. ICP4 and ICP0 were detected in the pellet as
early as 3 h pi, whereas gB was detected primarily in the
supernatant 5 and 7 h pi and RPLPO was detected in both the
supernatant and pellet (Fig. 5B). These findings are consistent with
the qRT-PCR results (Fig. 5A) and suggest that B5 interacts with
immediate early gene transcripts to promote their translation.
B5 is required for translation of viral ICP0 and ICP4
The observation that silencing of B5 led to a reduction in HSV
immediate early proteins without affecting mRNA expression
suggests that B5 is required for translation of the viral immediate
early proteins. Specifically, silencing could interfere with mRNA
processing, such as polyadenylation, nuclear export, the associa-
tion of RNA with ribosomal subunits or polysomes and/or
translation of the mRNA to protein. To address these possibilities,
additional experiments were conducted. Transfected cells were
infected with HSV-2(G) (3 pfu/cell) and 3 h pi, cells were
harvested and nuclear and cytoplasmic fractions isolated. Gol-
gin97 and histone-1 were detected in the cytoplasmic and nuclear
fractions, respectively, confirming the purity of the fractionation.
B5 and ICP4 were detected in the cytoplasm of cells transfected
with control siHVEM, but expression was markedly reduced or
absent in cells transfected with siB5 (Fig. 6A). Polyadenylated
mRNA was purified from the total isolated RNA and from the
cytoplasmic and nuclear fractions and visualized in a formalde-
Figure 5. Viral RNA and immediate early proteins associate with B5 in RNA-protein complexes. (A) Cells were infected with HSV-2(G) and
3, 5, or 7 h pi, the cells were treated with 0.04% of methanol-free formaldehyde to cross-link RNA-protein complexes. The complexes were
immunoprecipitated with a polyclonal rabbit anti-B5. and RNA was extracted from the supernatant and pellet and analyzed for the expression of viral
transcripts and RPLPO. Results are shown for the time pi at which peak expression of viral transcripts was detected (3 h for ICP4, 5 h for ICP0 and 7 h
for gB) and are presented as the ratio of viral transcript/RPLPO in each fraction to the viral transcipts/RPLPO in the total RNA-protein complex from
infected cells prior to immunoprecipitation (input). Expression of RPLPO is presented as the ratio of RPLPO in each fraction to RPLPO in the total RNA-
protein complex from uninfected cells prior to immunoprecipitation (input). (B) The supernatant and pellet from the immunoprecipitated complexes
isolated at 0, 3, 5, and 7 h pi were evaluated for the expression of ICP4 (HSV-2), gB (HSV-2), ICP0 (HSV-1) or RPLPO by Western blots. Blots are
representative of results obtained in at least 3 independent experiments.
doi:10.1371/journal.pone.0011829.g005
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detected (not shown) and similar proportions of ICP4 polyadenyl-
ated mRNA were detected by qRT-PCR in both the nuclear and
cytoplasmic fractions in cells transfected with siHVEM or siB5
(Fig. 6B). Together, these results indicate that B5 silencing had no
deleterious impact on polyadenylation or nuclear export of RNA.
To determine if silencing of B5 impacted the ability of viral
transcripts to associate with ribosomal subunits or polysomes,
polysome fractions were isolated from cells that had been
transfected with siHVEM (control) or with siB5 by centrifugation
through 10–50% sucrose gradients. The UV absorbance pattern of
fractions derived from cells that had been transfected with siB5
differed from the pattern observed in siHVEM transfected cells,
consistent with B5 playing a role in the formation of ribosomal
subunits (Fig. 7A, left). RNA was isolated from each fraction and
analyzed for expression of GAPDH by reverse-transcription and
PCR and, in parallel studies, the proteins in each fraction were
analyzed by Western blot for cytolasmic poly(A)-binding protein 1
(PABP), which is a general translation factor for mRNA, and for B5.
GAPDH and PABP were present across the gradient from both
siHVEM and siB5 transfected cells, although modest differences in
relative amounts expressed in various fractions were observed
(Fig. 7A, right). B5 protein was detected predominantly in fractions
7–9 of the siHVEM control cells, coinciding with the 80S ribosomal
subunit, and was absent in the siB5 transfected cells.
Parallel studies were conducted following infection with HSV-2.
Consistent with published studies, the gradient profile following
viral infection in the control (siHVEM) cells showed reduced levels
of the ribosomal subunits compared to uninfected cells, presum-
ably reflecting viral-induced shutoff of host protein synthesis
(Fig. 7B, left) [20]. The gradient profile was further altered in the
siB5-transfected cells, possibly reflecting the combined effects of
silencing and viral infection. GAPDH was again distributed across
the gradient in fractions isolated from infected cells transfected
with either siHVEM or siB5, but ICP4 transcripts were only
detected in the fractions isolated from the control (siHVEM) cells
and were found primarily in fractions 6–8, which coincides with
the fractions containing B5 protein (Fig. 7B, right). Similarly,
Western blots demonstrated that ICP4 polypeptides could only be
detected in the fractions isolated from control, but not siB5
transfectants (Fig. 7B, right)). Taken together, these results suggest
that in the absence of B5, ICP4 transcripts fail to associate with
ribosomal subunits, resulting in a block in translation.
B5 silencing has a greater impact on HSV than VSV or HIV
infection
Studies were extended to other cell types and other viruses to
explore whether B5 also played a major role in protein synthesis
and infection. Silencing of B5 inhibited HSV infection of HaCAT
cells (human keratinocyte) and murine fibroblasts (not shown).
Moreover, there was a reduction in ICP0 protein expression in
siB5 transfected Jurkat-TAT-CCR5 cells following HSV-1 infec-
tion (Fig. 8A, left). In contrast, silencing of B5 in these cells had a
non-significant impact on HIV infection as measured by p24 in
culture supernatants (p=0.2) (Fig. 8A, right). Transfection of
CaSki cells with siB5 had more modest effects on VSV (p=0.03)
relative to the inhibitory effects on HSV (p=0.002) (Fig. 8B).
Silencing of eIF2a, but not B5, is cytotoxic
Most studies of interactions between HSV and host cell initiation
factors have focused on eIF2a because of its established role in host
defense. A major cellular response to viral infection (or other stress)
is to inactivate eIF2a by phosphorylation. HSV overcomes this host
response through the actions of at least two viral proteins, ICP34.5
and Us11, which cooperate to restore eIF2a pools [21]. While eIF2,
a heterotrimer composed of three subunits, is essential for protein
synthesis, the precise role eIF2a, the regulatory subunit, plays in
HSV protein translation has not been established. Thus, we
compared the impact of silencing eIF2a and B5 on viral infection.
Transfection of CaSki cells with sieIF2a efficiently silenced its
expressionby,80%;siB5hadlittleornoeffectoneIF2a expression
(Fig. 9A). Transfection with either siB5 or sieIF2a reduced ICP4
expression as detected by Western blots of infected cellular lysates
4 h pi (Fig. 9B) and also inhibited viral plaque formation by at least
one log (not shown). However, there was a marked difference in the
effects of silencing on cell viability. Silencing of eIF2a reduced cell
viability by ,50% 3 days post-transfection, whereas siB5 had little
effect (Fig. 9C). The cytotoxic effects observed with sieIF2a were
comparable to those observed with the detergent N-9 [22]. These
results suggest that B5 may provide a safer and more specific target
to block HSV protein synthesis.
B5 provides a target for prevention of primary or
recurrent HSV
Currently, the primary modality for treatment or suppression of
HSV infections is acyclovir, which interferes with viral DNA
Figure 6. B5 silencing does not block polyadenylation or
nuclear export of RNA. (A) Transfected cells were infected with HSV-
2(G) (moi 3 pfu/cell) and 3 h pi, cells were harvested and nuclear and
cytoplasmic fractions isolated and Western blots were prepared and
probed for golgin97, histone-1, B5 and ICP4. (B) Polyadenylated mRNA
was isolated from the total RNA and from the cytoplasmic and nuclear
fractions and then analyzed for ICP4 by qRT-PCR. Results are presented
as the ratio of ICP4/RPLPO in each fraction (cytoplasmic or nuclear) to
ICP4/RPLPO in the unfractionated total polyA RNA and are represen-
tative of 3 independent experiments.
doi:10.1371/journal.pone.0011829.g006
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on viral infection alone, or in combination. Cells were transfected
with siB5 or siHVEM and then challenged with serial dilutions of
HSV-2(G) in the absence or presence of 100mg/ml acyclovir and
the viral plaques determined. Treatment with acyclovir or
transfection with siB5 each independently reduced viral plaque
formation by ,2-logs and, when combined, resulted in ,3-log
reduction (Fig. 10A), indicating that the two interventions target
different steps in the viral life cycle. To explore whether targeting
of B5 could block the amplification of virus that had reactivated,
we used an explant co-cultivation model. Sacral ganglia were
removed from vaginally infected mice and co-cultured for two
weeks with CaSki cells that had been transfected with siB5 or
control siRNA; viral amplification was monitored by collecting a
portion of the culture supernatants and assaying for the presence
of virus by plaque assay. Little or no virus was detected in culture
supernatants harvested from co-cultures of sacral ganglia and B5-
silenced cells, whereas .10
4 pfu/ml were recovered from co-
cultures of ganglia with cells transfected with control siRNA in two
independent experiments (not shown).
To further explore the potential safety of targeting B5 to reduce
primary or recurrent HSV, the effects of B5 silencing on the
overall pattern of host protein synthesis were examined by
metabolic labeling the cells 72 h post-transfection. Little change
in host cell protein expression was observed (Fig. 10B, left); the
efficiency of silencing was confirmed by Western blots (Fig. 10B,
right). These findings, coupled with the lack of cytotoxicity in B5
transfected cells (Fig. 9C) indicate that B5 is not essential for host
cell protein translation and support the notion that B5 could
provide a novel target for antiviral therapeutic strategies.
Discussion
Productive HSV infection requires the translation of viral
proteins and is associated with the selective inhibition of host
protein synthesis. While substantial work has focused on
delineating how HSV triggers the shutoff of host protein synthesis,
far less is known about the molecular mechanisms that promote
viral protein synthesis. The results of this study begin to address
this gap. Specifically we found that B5, which has been recently
identified as eIF3m, plays a key role in promoting the initial
translation of HSV immediate early proteins, ICP4 and ICP0. The
pivotal role B5 (eIF3m) plays in initiating the synthesis of HSV
immediate early proteins may be relatively specific, as silencing of
Figure 7. Silencing of B5 prevents HSV ICP4 transcripts from associating with ribosomes. (A). Cytoplasmic extracts of CaSki cells
transfected 48 h earlier with siHVEM or siB5 were fractionated on 10% to 50% sucrose gradients and the UV absorbance at 254 nm of each fraction
(bottom to top of the sucrose gradient) measured; the relative positions of 40S and 60S ribosomal subunits, 80S monosomes and polysomes are
indicated (left). The RNA from each fraction was analyzed for GAPDH expression by reverse transcription and PCR. Alternatively, fractions were
analyzed for expression of PABP and B5 by Western blot (right). (B). Cytoplasmic extracts from HSV-2 infected cells that had been transfected 48 h
earlier with siHVEM or siB5 were fractionated on 10% to 50% sucrose gradients and the UV absorbance at 254 nm of each fraction measured (left).
The RNA from each fraction was analyzed for GAPDH or ICP4 expression by reverse transcription and PCR and the expression of ICP4 protein by
Western blot (right).
doi:10.1371/journal.pone.0011829.g007
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or no impact on host cellular proteins including eIF2a and nectin-
1. The exact determinant that regulates which viral or cellular
transcripts will interact with B5 requires further study.
Currently at least 12 eIFs, composed of at least 29 distinct
subunits, have been identified [23]. The largest mammalian
initiation factor, eIF3, plays an essential role in translation by
binding directly to the 40S ribosomal subunit to recruit mRNAs
that bear a methylated guanosine cap at the 59-end and promote
formation of the 43S preinitiation complex. Mammalian eIF3
consists of 13 non-identical subunits, eIF3a through eIF3m;
subunit m was the most recently discovered [15]. The functions of
the individual subunits in human cells are not yet well
characterized. In the yeast Saccharomyces cerevisiae, eIF3 consists of
a core complex of five stoichiometric subunits (eIF3a, -b, -c, -g,
and -i), plus a non-stoichiometric subunit, eIF3j. In mammalian
cells, the corresponding homologues also may constitute a ‘‘core’’
complex to which the other mammalian subunits bind and
regulate eIF3 activity. The finding that silencing of B5 had little
effect on cell viability and that it did not adversely impact
expression of the cellular proteins studied is consistent with the
notion that eIF3m is not an essential core element. However,
further studies are needed.
The notion that distinct subclasses of eIF3 complexes,
containing different combinations of core and non-core subunits,
may regulate specific subsets of mRNA has been suggested in
studies with fission yeast, where biochemically distinct eIF3
complexes defined by the PCI domain proteins eIF3e and eIF3m
associate with different sets of mRNAs [24]. Tandem mass
spectrometry demonstrated that eIF3m is likely to be on the
periphery of the eIF3 complex, and possibly accessible to viral
mRNA [15]. Additionally, time-resolved spectroscopy has shown
that the B5 C-terminus forms a reversible structure that might
allow it to interact with proteins, viral RNA or RNA-protein
complexes [25]. Notably, a recent study found that eIF3m may
also play a role in regulating caspase 9 responses to apoptotic
stimuli [26].
Previous studies have explored interactions between HSV
proteins and eIF4 and eIF2a. Specifically, ICP0 and ICP6
stimulate the assembly of eIF4F complexes, which facilitate
subsequent viral protein synthesis [27,28]. However, these
interactions must occur downstream of the interactions between
Figure 8. B5 silencing has more modest effects on HIV or VSV infection. (A) Jurkat-TAT-CCR5 cells were transfected with siHVEM (control) or
B5 specific siRNA and 48 h post-transfection, immunoblots of cell lysates were prepared and probed with anti-B5 polyclonal Ab (upper panel).
Transfected cells were infected with HSV-1(KOS) and 4 h pi, cell lysates prepared and analyzed for ICP0 expression (middle panel) and b-actin as a
loading control (lower panel). In parallel, the transfected cells were infected with HIV-1(BaL) and culture supernatants harvested 5 days pi and
analyzed for p24 expression (right). (B) CaSki cells were transfected with HVEM or B5 specific siRNA and 48 h post-transfection immunoblots of cell
lysates were prepared and probed with anti-B5 polyclonal Ab (upper) and b-actin as a loading control (lower panel). The transfected cells were
infected with HSV-2(G) or VSV and plaques counted 48 h pi; results are means 6 sd obtained from two independent experiments conducted in
duplicate.
doi:10.1371/journal.pone.0011829.g008
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to antagonize eIF2a phosphorylation, which would prevent
formation of the 80S ribosomal complex and thus block viral
protein synthesis, has been extensively studied. Results of the
current studies are consistent with the role of eIF2a in viral protein
translation, as silencing reduced HSV gene expression and plaque
formation (Fig. 9). However, silencing of eIF2a is toxic to cells and
thus would not provide a target for antiviral therapies.
The observation that both acyclovir and siB5 markedly inhibit
HSV infection by different mechanisms supports the notion that
targeting of B5 could provide a novel strategy to prevent primary
and recurrent HSV infections. This is critical, not only because of
the morbidity associated with HSV infection itself, but because of
the synergy between HSV and HIV. In recently completed clinical
trials, suppressive acyclovir therapy failed to reduce the risk for
HIV acquisition [29]. One possible explanation for this comes
from recent work showing the persistence of activated immune
cells in sequential biopsies of HSV-2 lesions from patients on
suppressive antiviral therapy [30]. Acyclovir inhibits viral
replication, but does not prevent viral reactivation or block viral
protein expression, and therefore may not prevent the recruitment
and activation of HSV-specific T cells. Results obtained in this
work suggest that B5 silencing might prevent the amplification of
reactivating virus and possibly limit the recruitment and activation
of T cells, which may serve as HIV targets.
The discovery that B5 plays a key role in promoting the
synthesis of HSV immediate early proteins was serendipitous. The
original observation that B5 may contribute to HSV infection
came from studies with porcine cells that are resistant to HSV
entry and did not address the translation of viral proteins.
Transfection of the porcine cells with a human cDNA expressing
B5 rendered the cells fully susceptible to HSV [11]. However, in
ongoing work, we found that B5 does not play a direct role in
mediating entry into the porcine cells, but acts indirectly and
modulates the expression of porcine nectin, rendering it accessible
to bind viral gD (work in progress). Notably, we observed no
Figure 9. Silencing of eIF2a, but not B5, is cytotoxic. (A) Cells were transfected with HVEM, eIF2a or B5 specific siRNA or no transfection (media)
and 48h later, evaluated for the expression of eIF2a and b-actin (control) by Western blot; blots are representative of 2 independent experiments. (B)
Cells were treated with media or transfected with siB5, sieIF2a, or siHVEM and then 48h later, infected with HSV-2(G) and 4h pi, cell lysates were
prepared and evaluated for expression of viral ICP4 and b-actin; a representative blot from 3 independent experiments is shown (left). The blots were
scanned and results are presented as odu relative to cells treated with media (mean + sd from 3 experiments). (C). Cells were grown on 96-well plates,
transfected with siB5 or sieIF2a or treated with 0.1% N-9, Effectene, or untreated and then quadruplicate wells were evaluated daily for 5 days for cell
viability using an MTT assay. Results are presented as percent viability relative to untreated cells and are means 6 sd obtained from 2 independent
experiments.
doi:10.1371/journal.pone.0011829.g009
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conclusion, the current studies demonstrate that B5 (eiF3m) plays
a major role in promoting the translation of HSV immediate early
proteins and may be a novel target for prevention strategies.
Materials and Methods
Cells and Viruses
CaSki cells (human cervical epithelial cell line) were obtained
from American Tissue Culture Collection (ATCC CRL 1550) and
were passaged in DMEM supplemented with 10% fetal bovine
serum. Jurkat-Tat-CCR5 cells, a T-cell line transfected with the
HIV-1 tat gene and the CCR5 coreceptor, were cultured in
complete RPMI supplemented with 250 mg/ml hygromycin B (for
Tat selection) and 500 mg/ml geneticin (for CCR5 selection) as
previously described [31]. HSV-2(G), HSV-1(KOS), and HSV-
1(KVP26GFP), which contains a green fluorescent protein (GFP)–
VP26 fusion protein [16] were prepared from infected Vero cell
cultures (ATCC CCL81) and viral stocks were stored at 280uC.
HIV-1BaL was grown in PM-1 cells and stored at 280uC after
filtration through 0.2 mm filters (Millipore, MA). VSV-Indiana was
grown on Vero cells.
Figure 10. Acyclovir and B5 silencing inhibit HSV infection and silencing has little impact on host cell protein synthesis. (A). Cells
were either transfected with HVEM or B5 specific siRNA or not transfected, and then infected with serial dilutions of HSV-2(G) (0.001–1000 pfu/cell) in
the absence or presence of acyclovir (ACV) (100mg/ml) and 48 h pi, cells were fixed and viral plaques counted. Only wells with 20–150 pfu were
counted to determine the viral titer (pfu/ml). (B). Transfected cells were metabolically labeled 72 h post-transfection and analyzed by gel
electrophoresis followed by autoradiography. Results are representative of 3 independent experiments (left). Immunoblot of cells 72 h post-
transfection probed with antibodies to B5 and b-actin (right).
doi:10.1371/journal.pone.0011829.g010
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To label viral envelopes, Vero cells were infected with wild-type
viruses or KVP26GFP virus (,0.001 pfu/cell) and after 48 h, the
infected cells were lysed and then incubated with lypophilic tracers
DiO or DiI (1 mM) (Molecular Probes, Invitrogen Valencia, CA)
for 10 min at room temperature before purification on sucrose
gradients [4].
siRNA and transfections
Cells were transfected with 100pmol/well (12-well plates) of the
indicated siRNA by using the Effectene transfection reagent
(QIAGEN, Valencia, CA) as described previously [17]. Nectin-1
siRNA (ID214887,12154,111208) B5 siRNA (ID122597,122596,
122595), HVEM siRNA (ID13772,111368,214894), eIF2a siRNA
(ID33496,125660,125659) and control siRNA (Silencer negative
control siRNA#1, AM4636) were purchased from Applied Biosys-
tems (Ambion; Austin, TX) Cells were analyzed for protein
expression by preparing Western blots of cell lysates and for gene
expression by qRT-PCR (see below).
Viral infection and VP16 assays
Transfected or control cells were infected with serial dilutions of
virus for 1 h at 37uC, inoculum removed, and cells overlaid with
medium in the absence or presence of acyclovir (100mg/ml)
(American Pharmaceutical Partners, Schaumburg, IL) for 48 h.
Plaques were counted by immunoassay using an anti–human IgG
antibody peroxidase conjugate (Calbiochem) [32]. For synchro-
nous infections, cells were precooled and exposed to virus at 4uC
for 4 h to allow binding. Unbound virus was removed by washing,
and the cells were transferred to 37uC to allow viral penetration
for 45 min. For VSV, CaSki cells that had been transfected with
siRNA 48 h earlier were infected with serial dilutions of VSV,
overlaid with 1% methylcellulose, fixed after 24 h with methanol,
and plaques counted after staining with Giemsa.
To examine transport of VP16 to the nucleus, nuclear extracts
were prepared 45 min after infection and analyzed by Western
blots as described previously [10]. To examine viral protein or
gene expression, whole cell lysates were prepared and protein
expression examined by Western blots or RNA extracted for qRT-
PCR (below). In select experiments, cycloheximide (100mg/ml, C-
7698, Sigma-Aldrich) was added to the overlay media for the
entire time of infection as a control for inhibition of protein
synthesis.
Total RNA extraction and real-time quantitative RT-PCR
(qRT-PCR)
Total RNA was extracted using an Absolutely RNA Miniprep
kit (Stratagene, La Jolla, CA). RNA (500ng) was reverse
transcribed with the High Capacity cDNA Reverse Transcription
kit (Applied Biosystems, Foster City, CA). Real-time PCR
amplification was performed using an Applied Biosystems
7900HT Real-Time PCR System and analyzed using the
sequence detector software. The reactions were performed using
the TaqManH Gene Expression Master Mix and the probes for
human nectin-1 (PVRL1) (Hs00161050_m1), HVEM
(TNFRSF14) (Hs00187058_m1), B5 (GA17) (Hs00272235_m1),
interferon alpha (IFNA1) (Hs00256882_s1) and RPLPO
(4310879E) were obtained from Applied Biosystems. Quantifica-
tion was normalized against the number of RPLPO transcripts in
the same RNA extracts.
To evaluate expression of HSV genes, primer and probe
sequences were designed using Primer Express (Applied Biosys-
tems) software and synthesized by Applied Biosystems as 206Mix.
The HSV-2 primers and probe used were as follows: 1) HSV2
ICP0: forward primer 59-GTGCATGAAGACCTGGATTCC-39;
reverse primer 59-GGTCACGCCCACTATCAGGTA-39;a n d
probe 59-FAM-TTGCGCAACACGTGTCCCCTG-TAMRA-39;
2) HSV-2 ICP4: forward primer 59-GCGAGCTGCGGTTCGT-
39; reverse primer 59-GCCACGCGCAGGTC-39; and probe 59-
FAM-CAGGCGCATCAGCACC-TAMRA-39; 3) HSV-2 gB:
forward primer 59-CTCGCCGAGCTGTACGT-39; reverse prim-
er 59-CGGGCGTGGCATTCC-39; and probe 59-FAM-CTCC-
CGCATGTACTCC-TAMRA-39.
Antibodies for Western blots and confocal microscopy
Antibodies and dilutions were as follows: anti-nectin murine
monoclonal antibodies (mAbs), 1:500 (sc-21722, Santa Cruz
Biotechnology, Santa Cruz, CA); anti-VP16 mAb, 1:500
(sc7545; Santa Cruz Biotechnology); anti-ICP27 mAb, 1:2000
(ab31631, Abcam, Cambrige, Ma), anti-ICP4 mAb 1:500 (P1101,
Virusys Corporation, Sykesville,MD), anti-ICP0 mAb, 1:500
(H1A027-100,Virusys); anti-gB mAb, 1:500 (HA056-100, Virusys);
anti-gD mAb, 1:1000 (P1103, Virusys), anti-b-actin mAb, 1:5000
(A-5441; Sigma-Aldrich, St. Louis, MO), anti-HVEM mAb 1:200
(ab374820, Abcam), anti-B5 rabbit polyclonal, 1:500 (ab69842,
Abcam), anti-eIF2a 1:500 (ab5369), anti-histone H1, 1:1000 (sc-
8030; Santa Cruz Biotechnology),anti-golgin97, 1:500 (A-21270,
Invitrogen), anti-RPLP0 1:500 (ab88872, Abcam) and anti-PABP
mAb, 1:500 (sc-32318; Santa Cruz Biotechnology). The secondary
antibodies for Western blots were horseradish peroxidase-conju-
gated goat anti-mouse, 1:1000 (170–5047, Bio-Rad, Hercules,
CA), or goat anti-rabbit 1:1000 (170–5046, Bio-Rad).
Confocal Microscopy
Cells were grown on glass coverslips in 12-well plates,
transfected with siRNA as described above, and, if indicated, 24
or 48 h post-transfections, synchronously infected with DiI-labeled
HSV-1(KVP26GFP). To label plasma membranes, the cells were
stained for 30 min with EZ-Link sulfosuccinimidobiotin (EZ-Link
Sulfo-NHS-Biotin) reagent (0.1 mM; Pierce Chemical, Rockford,
IL), which reacts with primary amines on cell-surface proteins
before infection, fixed with 4% paraformaldehyde solution
(Electron Microscopy, Hatfield, PA) at the indicated times pi,
and the biotinylated cells were reacted with Alexa Fluor 350-
conjugated streptavidin (1:1000 dilution; S11225, S11249; Invi-
trogen, Carlsbad, CA). Images were acquired by laser confocal
microscope ZeissLive/DuoScan equipped with an oil immersion
objective 6361.4. Images were captured in an optical slice of
,0.5 mm with appropriate filters, Alexa Fluor 488, and GFP were
excited using the 488-nm line of a krypton/argon laser and viewed
with a 505- to 530-nm band pass mm. AlexaFluor 360 were excited
with 405-nm diode laser and collected with 420-to 475 nm filter,
Alexa 546 were excited using 543-nm helium/neon laser and
collected with a 575- to 655 filter. All images were captured using
the multitrack mode of the microscope to decrease cross talk of
fluorescent signals. Z-sections were captured in an optical slice of
0.5 mm.
Live image microscopy was performed to examine calcium
signaling in response to HSV. Cells were grown in glass bottom
culture dishes 35 mm (product no. P35G-1.5-10-C; MatTek
corporation, Ashland, MA) and labeled with EZ-Link and 350-
conjugated streptavidin (1:1000 dilution; S11225, S11249; Invi-
trogen). The cells were then loaded with Calcium Crimson (C-
3018, 2.5mg/ml, Invitrogen) for 4 h at 4uC, and infected with
DiO-labeled virus for 4 h at 4uC. Cells were washed three times
with PBS to remove extracellular Ca
2+ and unbound virus,
overlaid with 25 mM HEPES buffer, and placed into a
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ive/DuoScan confocal microscope fitted with a 10061.4 oil
objective. Images were acquired 10 min after the dishes were
placed in the chamber. Image analysis was conducted using the
LSM confocal software package (Carl Zeiss, Inc.) and quantifica-
tion of intensity staining with image J software (National Institutes
of Health, Bethesda, MD). Three-dimensional (3-D) images were
generated using the Volocity 4 confocal software (Improvision,
Lexington, MA).
RNA-protein complexes and immunoprecipitation
CaSki cells were grown on 25cm
2 flasks, transfected with siRNA
at 800pM per flask using the Effectene transfection reagent
(QIAGEN, Valencia, CA) and 48h post-transfection, the cells were
infected with HSV2(G) (moi 2 pfu/cell). Three, 5 or 7 h pi, the
cells were treated with 0.04% of methanol-free formaldehyde (RT
15680, Electron Microscopy sciences, Hatfield, PA) to cross-link
RNA-protein complexes or with PBS as a control and immuno-
precipitated with a polyclonal rabbit anti-B5 antibody in RIPA
buffer (Sigma-Aldrich) supplemented with complete protease
inhibitors (Roche Diagnostics) as described [33]. The RNA was
purified from the supernatant and the precipitated complexes
(pellet) and analyzed by qRT-PCR using primers for ICP4, ICP0,
gB or RPLPO. Quantifications were normalized per input RNA.
Enrichment was defined as the ratio of normalized number of viral
transcripts in each fraction relative to transcripts in the input (non-
immunoprecipitated). Immunoblots were also prepared and
analyzed for viral proteins or RPLPO.
Polyadenylated RNA extraction
Subconfluent CaSki cells were transfected with 800pmol/well
(T25 dish) of siHVEM or siB5 and then 48 h post-transfection were
infected with HSV2(G) (3 pfu per cell). Three hours pi, cells were
harvested and dissolved into iso-hi-pH buffer [10mM Tris pH 8.4,
140mM NaCl, 1.5mM MgCl2, 0.5% NP-40] supplemented with
10mM VRC (S1402S, New England BioLabs, Ipswich, MA).
Nuclei were pelleted for 10 min at 1500 rpm, washed twice in iso-
hi-pH and once in iso-hi-pH supplemented with 0.1 volume of
Tween-deoxycholatesolution,pelletedthrougha2.2 Msucrose pad
for 30 min at 16,000 rpm, and washed again in iso-hi-pH. To
examine the purity of isolated cellular fractions, Western blots were
performed using golgin97 and histone H1 as markers of cytoplasm
and nuclear fractions, respectively. Total RNA was purified from
the total cellular lysates, cytoplasmic and nuclear fractions by
TRIzol, and polyadenylated mRNA was subsequently isolated from
the total RNA preparations using Absolutely mRNA
TM purification
kit (400806, Stratagene) and visualized by formaldehyde denaturing
gels. Expression of ICP4 was detected by qRT-PCR.
Isolation of polysomes
Subconfluent CaSki cells were transfected with 800pmol/well
(T25 dish) of siHVEM or siB5 and then 48 h post-transfection
were left uninfected or were infected with HSV2(G) (3 pfu per cell)
for 3 h. Both the uninfected and infected cells were trypsinized
and the cell pellets were rinsed twice with ice-cold PBS and
resuspended in gradient buffer [50mM Tris-HCL (pH 7.5), 80mM
KCl, 5mM MgOAc, 2 mM DTT, 1% sucrose] containing 1 unit/
ml of RNase inhibitor (RNAsin, N2611, Promega, Madison, WI)
and supplemented with complete protease inhibitors (Roche). Cells
were lysed by sonication, subjected to centrifugation (16,000 rpm
for 10 min at 4uC) and then layered on top of an 11-ml linear 10–
50% sucrose gradient. Samples were centrifuged at 27,500 rpm in
a Beckman SW41 ultracentrifuge rotor for 4 h. Gradients were
fractionated from the bottom (1 ml fractions) and analyzed for
PABP, B5 or ICP4 by Western blotting. Alternatively, the RNA in
each fraction was purified with TRIzol LS reagent (Life
Technologies, Gaithersburg, MD) followed by phenol-chloroform
extraction and ethanol precipitation and dissolved into 10 mlo f
RNAase free water. The fractions were assayed for absorbance at
254 nm with a Nano Drop spectrophotometer. To evaluate for
ICP4 transcripts, 2ml of RNA recovered from each fraction were
subjected to reverse transcription and then the cDNA was
amplified with primers specific for ICP4 or GAPDH (ICP4:
forward 59-GTACGTCAGCGGGGAGCC-39 and reverse 59-
GTCGCCGTCGAAGCCCTC-39; GADPH: forward 59-
GCATGGCCTTCCGTGTCCC C-39 and reverse 59-
TGGCAGGGACTCCCCAGCAG-39. DNA was visualized by
electrophoresis in 1% agarose.
HIV infection and p24 assay
Jurkat-TAT-CCR5 cells were infected with HIV-1 BaL (4ng of
p24 per 10
4 cells) for 2 hours and then washed and overlaid with
RPMI growth media. Culture supernatants were collected and viral
replication was assessed using a p24 enzyme-linked immunosorbent
assay (ELISA; p24 antigen capture assay kit; NCI-Frederick Cancer
Research and Development Centre, AIDS Vaccine Program).
S
35–methionine labeling of cellular proteins
CaSki cells (60% confluent 6-well plates) were transfected with
siHVEM and siB5 RNA at 160pM per well using Effectene
transfection reagent in DMEM without L-methionine and L-cystine
(21013-024, GIBCO), supplemented with 0.3mCi/ml of L-S
35-
methionine (6009, 1175Ci/mmol, NE). The cells were harvested
72 h post-transfection and analyzed in a 4–20% gradient
polyacrylamide gel(161–1105, Bio-Rad), followed by autoradiogra-
phy using HyBlot CL film (E3018, Denville Scientific Inc.).
Acknowledgments
We thank Prashant Desai (Johns Hopkins University) for the KVP26GFP
virus. We thank Frank Macaluso and the Analytical Imaging Facility at
Albert Einstein College of Medicine for assistance with confocal laser




Conceived and designed the experiments: NVC JT BCH. Performed the
experiments: NVC JT TJS. Analyzed the data: NVC JT TJS BCH.
Contributed reagents/materials/analysis tools: AOF. Wrote the paper: JT
TJS AOF BCH.
References
1. Wilson SS, Fakioglu E, Herold BC (2009) Novel approaches in fighting
herpes simplex virus infections. Expert Rev Anti Infect Ther 7: 559–
568.
2. Roberts C (2005) Genital herpes in young adults: changing sexual behaviours,
epidemiology and management. Herpes 12: 10–14.
3. Roberts CM, Pfister JR, Spear SJ (2003) Increasing proportion of herpes simplex
virus type 1 as a cause of genital herpes infection in college students. Sex Transm
Dis 30: 797–800.
4. Cheshenko N, Liu W, Satlin LM, Herold BC (2007) Multiple receptor
interactions trigger release of membrane and intracellular calcium stores critical
for herpes simplex virus entry. Mol Biol Cell 18: 3119–3130.
5. WuDunn D, Spear PG (1989) Initial interaction of herpes simplex virus with
cells is binding to heparan sulfate. J Virol 63: 52–58.
6. Herold BC, WuDunn D, Soltys N, Spear PG (1991) Glycoprotein C of herpes
simplex virus type 1 plays a principal role in the adsorption of virus to cells and
in infectivity. J Virol 65: 1090–1098.
B5 Is HSV Translational Factor
PLoS ONE | www.plosone.org 12 July 2010 | Volume 5 | Issue 7 | e118297. Cheshenko N, Herold BC (2002) Glycoprotein B plays a predominant role in
mediating herpes simplex virus type 2 attachment and is required for entry and
cell-to-cell spread. J Gen Virol 83: 2247–2255.
8. Montgomery RI, Warner MS, Lum BJ, Spear PG (1996) Herpes simplex virus-1
entry into cells mediated by a novel member of the TNF/NGF receptor family.
Cell 87: 427–436.
9. Geraghty RJ, Krummenacher C, Cohen GH, Eisenberg RJ, Spear PG (1998)
Entry of alphaherpesviruses mediated by poliovirus receptor-related protein 1
and poliovirus receptor. Science 280: 1618–1620.
10. Cheshenko N, Del Rosario B, Woda C, Marcellino D, Satlin LM, et al. (2003)
Herpes simplex virus triggers activation of calcium-signaling pathways. J Cell
Biol 163: 283–293.
11. Perez A, Li QX, Perez-Romero P, Delassus G, Lopez SR, et al. (2005) A new
class of receptor for herpes simplex virus has heptad repeat motifs that are
common to membrane fusion proteins. J Virol 79: 7419–7430.
12. Subramanian G, LeBlanc RA, Wardley RC, Fuller AO (1995) Defective entry of
herpes simplex virus types 1 and 2 into porcine cells and lack of infection in
infant pigs indicate species tropism. J Gen Virol 76(Pt 9): 2375–2379.
13. Perez A, Fuller AO (1998) Stable attachment for herpes simplex virus
penetration into human cells requires glycoprotein D in the virion and cell
receptors that are missing for entry-defective porcine cells. Virus Res 58: 21–34.
14. Perez-Romero P, Fuller AO (2005) The C terminus of the B5 receptor for herpes
simplex virus contains a functional region important for infection. J Virol 79:
7431–7437.
15. Damoc E, Fraser CS, Zhou M, Videler H, Mayeur GL, et al. (2007) Structural
characterization of the human eukaryotic initiation factor 3 protein complex by
mass spectrometry. Mol Cell Proteomics 6: 1135–1146.
16. Desai P, Person S (1998) Incorporation of the green fluorescent protein into the
herpes simplex virus type 1 capsid. J Virol 72: 7563–7568.
17. Cheshenko N, Liu W, Satlin LM, Herold BC (2005) Focal adhesion kinase plays
a pivotal role in herpes simplex virus entry. J Biol Chem 280: 31116–31125.
18. Gelman IH, Silverstein S (1985) Identification of immediate early genes from
herpes simplex virus that transactivate the virus thymidine kinase gene. Proc
Natl Acad Sci U S A 82: 5265–5269.
19. Kutluay SB, DeVos SL, Klomp JE, Triezenberg SJ (2009) Transcriptional
coactivators are not required for herpes simplex virus type 1 immediate-early
gene expression in vitro. J Virol 83: 3436–3449.
20. Larralde O, Smith RW, Wilkie GS, Malik P, Gray NK, et al. (2006) Direct
stimulation of translation by the multifunctional herpesvirus ICP27 protein.
J Virol 80: 1588–1591.
21. Mohr I (2004) Neutralizing innate host defenses to control viral translation in
HSV-1 infected cells. Int Rev Immunol 23: 199–220.
22. Cheshenko N, Keller MJ, MasCasullo V, Jarvis GA, Cheng H, et al. (2004)
Candidate topical microbicides bind herpes simplex virus glycoprotein B and
prevent viral entry and cell-to-cell spread. Antimicrob Agents Chemother 48:
2025–2036.
23. Hinnebusch AG (2006) eIF3: a versatile scaffold for translation initiation
complexes. Trends Biochem Sci 31: 553–562.
24. Zhou C, Arslan F, Wee S, Krishnan S, Ivanov AR, et al. (2005) PCI proteins
eIF3e and eIF3m define distinct translation initiation factor 3 complexes. BMC
Biol 3: 14.
25. Brown OJ, Lopez SA, Fuller AO, Goodson T 3rd (2007) Formation and
reversible dissociation of coiled coil of peptide to the C-terminus of the HSV B5
protein: a time-resolved spectroscopic analysis. Biophys J 93: 1068–1078.
26. Chew SK, Chen P, Link N, Galindo KA, Pogue K, et al. (2009) Genome-wide
silencing in Drosophila captures conserved apoptotic effectors. Nature 460:
123–127.
27. Walsh D, Mohr I (2004) Phosphorylation of eIF4E by Mnk-1 enhances HSV-1
translation and replication in quiescent cells. Genes Dev 18: 660–672.
28. Walsh D, Mohr I (2006) Assembly of an active translation initiation factor
complex by a viral protein. Genes Dev 20: 461–472.
29. Celum C, Wald A, Hughes J, Sanchez J, Reid S, et al. (2008) Effect of aciclovir
on HIV-1 acquisition in herpes simplex virus 2 seropositive women and men
who have sex with men: a randomised, double-blind, placebo-controlled trial.
Lancet 371: 2109–2119.
30. Zhu J, Hladik F, Woodward A, Klock A, Peng T, et al. (2009) Persistence of
HIV-1 receptor-positive cells after HSV-2 reactivation is a potential mechanism
for increased HIV-1 acquisition. Nat Med 15: 886–892.
31. Mesquita PM, Wilson SS, Manlow P, Fischetti L, Keller MJ, et al. (2008)
Candidate microbicide PPCM blocks human immunodeficiency virus type 1
infection in cell and tissue cultures and prevents genital herpes in a murine
model. J Virol 82: 6576–6584.
32. Herold BC, Siston A, Bremer J, Kirkpatrick R, Wilbanks G, et al. (1997)
Sulfated carbohydrate compounds prevent microbial adherence by sexually
transmitted disease pathogens. Antimicrob Agents Chemother 41: 2776–2780.
33. Conrad NK (2008) Chapter 15. Co-immunoprecipitation techniques for
assessing RNA-protein interactions in vivo. Methods Enzymol 449: 317–342.
B5 Is HSV Translational Factor
PLoS ONE | www.plosone.org 13 July 2010 | Volume 5 | Issue 7 | e11829